Xenon Pharmaceuticals Inc. Common Shares (XENE)
Stock · NASDAQ · Health Care
$33.5as of 10/16/2026
Price chart
Active signals
XENE Signal Track Record
How signals performed across all stocks →What XENE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +3.4% | 60% | September 17, 2026 |
| Bollinger Band BreakdownActive now | 27 | +1.9% | 63% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 21 | -0.2% | 48% | September 15, 2025 |
| Bollinger Band Breakout | 20 | +3.0% | 60% | June 25, 2026 |
| Any 20-session window (baseline) | -0.4% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary genera…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 358
- Website
- www.xenon-pharma.com/
Fundamentals
- 1-day range
- $33.38$34.34
- Market cap
- $6.24B
- P/E (trailing)
- —
- P/E (forward)
- -7.09
- EPS (trailing)
- $-4.74
- Dividend yield
- —
- Beta
- 0.08
- Avg. volume
- 1.42M
How Xenon Pharmaceuticals Inc. Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
18 analyst ratings
Xenon Pharmaceuticals Inc. Common Shares Competitors
Chosen by industry and closest market cap.
- XENEXenon Pharmaceuticals Inc. Common Shares$33.49▼ 2.45%Market cap $6.24BP/E —$33.52$72.66
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
- BLTEBelite Bio Inc American Depositary Shares$142.78▼ 6.45%Market cap $6.32BP/E —$78.71$200
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals Inc. Common Shares | $6.24B | — | $33.49 | ▼ 2.45% | $33.52$72.66 |
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
| BLTE Belite Bio Inc American Depositary Shares | $6.32B | — | $142.78 | ▼ 6.45% | $78.71$200 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Callbenzinga · 10/12/2026
- This Biotech Surged 50% On Positive Data In March. Now, It's Completely Gone.Yahoo · 9/18/2026
- XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug TrialYahoo · 9/18/2026
- Top stock movements in today's session.ChartMill · 9/18/2026
- Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.Yahoo · 9/18/2026
- Sector Update: Healthcare Stocks Decline Friday AfternoonYahoo · 9/18/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/18/2026
- Xenon Pharmaceuticals falls 30% after depression trial enrollment pauseYahoo · 9/18/2026
- Xenon Pharmaceuticals' Azetukalner Retains Core Epilepsy Value, RBC Capital Markets SaysYahoo · 9/18/2026
Insider Activity
Insider Actions →- KENNEY CHRISTOPHER JOHN · August 28, 2026 · Sale700 @ $60.98
- KENNEY CHRISTOPHER JOHN · August 28, 2026 · Sale6.4K @ $60.17
- GANNON STEVEN · August 11, 2026 · Sale10.0K @ $64.06
- Cannon Gillian · June 5, 2026 · Sale1.2K @ $53.14
- PATOU GARY · June 5, 2026 · Sale1.3K @ $53.14
- Gover Justin D. · June 3, 2026 · Grant1.6K
- Gover Justin D. · June 3, 2026 · Grant10.5K
- Elizabeth A. Garofalo · June 3, 2026 · Grant1.6K
- Elizabeth A. Garofalo · June 3, 2026 · Grant10.5K
- GANNON STEVEN · June 3, 2026 · Grant1.6K
- GANNON STEVEN · June 3, 2026 · Grant10.5K
- Cannon Gillian · June 3, 2026 · Grant1.6K
- Cannon Gillian · June 3, 2026 · Grant10.5K
- Svoronos Dawn · June 3, 2026 · Grant1.6K
- Svoronos Dawn · June 3, 2026 · Grant10.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 101.35M
- Total value held
- $5.70B
- Institutional holders
- 286
- Unknown10.82M
- Unknown5.78M
- Unknown5.64M
- Unknown4.83M
- Unknown4.49M
- Unknown4.41M
- Unknown4.18M
- Unknown2.89M
- Unknown2.67M
- Unknown1.72M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target
Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).